Abstract
Approximately half of patients with schizophrenia have a lifetime diagnosis of substance abuse disorders. These dual diagnosis patients are more likely to have poorer outcomes, including more severe psychiatric symptoms with increased hospitalizations, higher utilization of services and frequent homelessness. Assessment and treatment of dually diagnosed patients has evolved over the last twenty years. To date, the strongest evidence for effective management of dual diagnosis patients has been utilization of integrated treatment services, which combines both mental health and substance abuse treatments concurrently. Strategies commonly used include a combination of pharmacological treatment, intensive case management, motivational interviewing, individual and group psychotherapy, and family participation. This chapter summarizes the treatment options available for this population.
Keywords: substance abuse and schizophrenic population, effective treatment of dual diagnosis patients
Current Pharmaceutical Design
Title: Treatment of Patients with Schizophrenia and Substance Abuse Disorders
Volume: 10 Issue: 18
Author(s): John Tsuang and Timothy W. Fong
Affiliation:
Keywords: substance abuse and schizophrenic population, effective treatment of dual diagnosis patients
Abstract: Approximately half of patients with schizophrenia have a lifetime diagnosis of substance abuse disorders. These dual diagnosis patients are more likely to have poorer outcomes, including more severe psychiatric symptoms with increased hospitalizations, higher utilization of services and frequent homelessness. Assessment and treatment of dually diagnosed patients has evolved over the last twenty years. To date, the strongest evidence for effective management of dual diagnosis patients has been utilization of integrated treatment services, which combines both mental health and substance abuse treatments concurrently. Strategies commonly used include a combination of pharmacological treatment, intensive case management, motivational interviewing, individual and group psychotherapy, and family participation. This chapter summarizes the treatment options available for this population.
Export Options
About this article
Cite this article as:
Tsuang John and Fong W. Timothy, Treatment of Patients with Schizophrenia and Substance Abuse Disorders, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384114
DOI https://dx.doi.org/10.2174/1381612043384114 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Endocannabinoid System in Parkinsons Disease
Current Pharmaceutical Design Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?
Current Drug Targets Pathological Gambling: Update on Decision Making and Neuro-functional Studies in Clinical Samples
Current Pharmaceutical Design Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Functional MRI of the Pancreaticobiliary System
Current Medical Imaging Data Visualization and Feature Selection Methods in Gel-based Proteomics
Current Protein & Peptide Science Advances in Lentiviral Vectors: A Patent Review
Recent Patents on DNA & Gene Sequences Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Adjunctive Depot Antipsychotic in Treatment-Resistant Schizophrenia
Current Psychopharmacology The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Current Neuropharmacology Causes of Secretion Retention: Patient Factors, Ventilation, Devices, Drugs
Current Respiratory Medicine Reviews Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Central Nervous System Agents in Medicinal Chemistry Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) Depot Based Drug Delivery System for the Management of Depression
Current Drug Delivery Botulinum Toxin: Pharmacology and Clinical Developments: A Literature Review
Medicinal Chemistry Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation
CNS & Neurological Disorders - Drug Targets Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis
Current Topics in Medicinal Chemistry